Vertaling van "associated with palliative care " (Nederlands → Frans) :

Peuckmann-Post V, Elsner F, Krumm N, Trottenberg P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care.
Peuckmann-Post V, Elsner F, Krumm N et al. Pharmacological treatments for fatigue associated with palliative care.

Bron Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD; Bernd Altkemper and Matthias Kohl, Center of Pain Management and Palliative Care (U.K.), Wiesbaden; Medi Ltd (B.A.), Bayreuth; and Statistics & Mathematics Service (StaMatS) (M.K.), Bayreuth, Germany Journal of Pain and Symptom Management Vol. 32 No. 4 oktober 2006.
Source Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD; Bernd Altkemper and Matthias Kohl, Center of Pain Management and Palliative Care (U.K.), Wiesbaden; Medi Ltd (B.A.), Bayreuth; and Statistics & Mathematics Service (StaMatS) (M.K.), Bayreuth, Germany Journal of Pain and Symptom Management Vol. 32 No. 4 October 2006.

In order to take care of monitoring, planning, coordinating and communicating about the numerous actions associated with the “FAGG-AFMPS 2008” project (see below), a support monitoring unit, the Program Management Office (PMO) unit, has been set up.
In order to take care of monitoring, planning, coordinating and communicating about the numerous actions associated with the “FAGG-AFMPS 2008” project (see below), a support monitoring unit, the Program Management Office (PMO) unit, has been set up.

Consistent with this focused research strategy, new Phase II data demonstrates that ACZ885, currently marketed as Ilaris for the rare disease cryopyrin-associated periodic syndrome (CAPS), provided highly statistically significant risk reduction of acute flares in gout patients compared to the anti-inflammatory standard of care.
Cette approche stratégique est illustrée par ACZ885, un médicament actuellement commercialisé sous la marque Ilaris pour traiter le syndrome périodique associé à la cryopirine (CAPS), une maladie rare. De nouveaux résultats d’une étude de phase II ont montré que ce médicament induisait une réduction importante, hautement significative sur le plan statistique, du risque de crises aiguës de goutte par comparaison avec le traitement anti-inflammatoire standard.